Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Annual Report 2023 Download

Documents

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor

Contact information

Investor Relations:

Email: IR@sequanamedical.com
Tel: +32 498 053579